The PGC-1α/HFN4α partnership plays a crucial role in hepatic lipoprotein metabolism (lipoprotein synthesis and export) (Rhee et al., 2006), and modulation of PGC-1α coactivation of HFN4α may provide a novel mechanism to manage dyslipidemia (Rhee et al., 2006). The gene discussed is PPARGC1A; the disease is metabolic syndrome.